ARHGEF25

Across TCGA pan-cancer cohorts, ARHGEF25 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGEF25 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARHGEF25 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF25 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where ARHGEF25 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	II,III,IV	0.300	0.893	.009	26	view →
PDAC	OS	Median	II,III,IV	0.698	0.326	.007	17	view →
LUAD	DFS	Tertile	II,III,IV	0.238	0.714	.014	9	view →
LSCC	OS	Tertile	II,III,IV	0.479	0.909	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARHGEF25–UCEC (DFS)

Open the UCEC breakdown →